BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Pancreatic cancer AND FOXP3, AIID, DIETER, IPEX, JM2, PIDX, XPID
169 results:

  • 1. An immunogenic cell death-related gene expression signature in predicting prognosis of pancreatic ductal adenocarcinoma.
    Wang X; Ren T; Liao C; Xie Y; Cao J
    BMC Genomics; 2024 Feb; 25(1):205. PubMed ID: 38395786
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Characterization of lymphocyte-rich hepatocellular carcinoma and the prognostic role of tertiary lymphoid structures.
    Ahn B; Ahn HS; Shin J; Jun E; Koh EY; Ryu YM; Kim SY; Sung CO; Shim JH; Hong J; Kim K; Kang HJ
    Liver Int; 2024 May; 44(5):1202-1218. PubMed ID: 38363048
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. High ANO1 expression is a prognostic factor and correlated with an immunosuppressive tumor microenvironment in pancreatic cancer.
    Zhang G; Shu Z; Yu J; Li J; Yi P; Wu B; Deng D; Yan S; Li Y; Ren D; Hou Y; Lan C
    Front Immunol; 2024; 15():1341209. PubMed ID: 38352864
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. CD3-CD8 immune score associated with a clinical score stratifies PDAC prognosis regardless of adjuvant or neoadjuvant chemotherapy.
    Schoumacher C; Derangère V; Gaudillière-Le Dain G; Huppe T; Rageot D; Ilie A; Vienot A; Borg C; Monnien F; Bibeau F; Truntzer C; Ghiringhelli F;
    Oncoimmunology; 2024; 13(1):2294563. PubMed ID: 38169969
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Identification of foxp3
    Gong R; Chen X; Sun X; Zhang Y; Wang J; Yu Q; Lei K; Ren H
    Am J Physiol Cell Physiol; 2024 Jan; 326(1):C294-C303. PubMed ID: 38047300
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma.
    Katz MHG; Petroni GR; Bauer T; Reilley MJ; Wolpin BM; Stucky CC; Bekaii-Saab TS; Elias R; Merchant N; Dias Costa A; Lenehan P; Cardot-Ruffino V; Rodig S; Pfaff K; Dougan SK; Nowak JA; Varadhachary GR; Slingluff CL; Rahma O
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040420
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Inhibition of USP7 upregulates USP22 and activates its downstream cancer-related signaling pathways in human cancer cells.
    Zhang K; Sun T; Li W; Guo Y; Li A; Hsieh M; Wang J; Wu J; Arvanitis L; Raz DJ
    Cell Commun Signal; 2023 Nov; 21(1):319. PubMed ID: 37946202
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Increased co-expression of PD1 and TIM3 is associated with poor prognosis and immune microenvironment heterogeneity in gallbladder cancer.
    He X; Peng Y; He G; Ye H; Liu L; Zhou Q; Shi J; Fu S; Wang J; Zhou Z; Li W
    J Transl Med; 2023 Oct; 21(1):717. PubMed ID: 37828574
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Prognostic value of circulating T-lymphocyte subsets in advanced pancreatic cancer patients treated with mFOLFIRINOX or gemcitabine.
    Tulyte S; Characiejus D; Matuzeviciene R; Janiulioniene A; Radzevicius M; Jasiunaite E; Zvirblis T; Sileikis A
    Int Immunopharmacol; 2023 Feb; 115():109722. PubMed ID: 37724957
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. The spatial coexistence of TIGIT/CD155 defines poorer survival and resistance to adjuvant chemotherapy in pancreatic ductal adenocarcinoma.
    Ma H; Chen X; Mo S; Mao X; Chen J; Liu Y; Lu Z; Yu S; Chen J
    Theranostics; 2023; 13(13):4601-4614. PubMed ID: 37649613
    [No Abstract]    [Full Text] [Related]  

  • 11. pH-Responsive Zinc Ion Regulating Immunomodulatory Nanoparticles for Effective cancer Immunotherapy.
    Lim B; Kim KS; Na K
    Biomacromolecules; 2023 Sep; 24(9):4263-4273. PubMed ID: 37616157
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Single cell transcriptomic analyses implicate an immunosuppressive tumor microenvironment in pancreatic cancer liver metastasis.
    Zhang S; Fang W; Zhou S; Zhu D; Chen R; Gao X; Li Z; Fu Y; Zhang Y; Yang F; Zhao J; Wu H; Wang P; Shen Y; Shen S; Xu G; Wang L; Yan C; Zou X; Chen D; Lv Y
    Nat Commun; 2023 Aug; 14(1):5123. PubMed ID: 37612267
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. The immune microenvironment after neoadjuvant therapy compared to upfront surgery in patients with pancreatic cancer.
    Zwart ES; van Ee T; Doppenberg D; Farina A; Wilmink JW; Versteijne E; Busch OR; Besselink MG; Meijer LL; van Kooyk Y; Mebius RE; Kazemier G
    J Cancer Res Clin Oncol; 2023 Nov; 149(16):14731-14743. PubMed ID: 37587309
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. A comprehensive analysis of tumor-stromal collagen in relation to pathological, molecular, and immune characteristics and patient survival in pancreatic ductal adenocarcinoma.
    Ashina S; Masuda A; Yamakawa K; Hamada T; Tsujimae M; Tanaka T; Toyama H; Sofue K; Shiomi H; Sakai A; Kobayashi T; Abe S; Gonda M; Masuda S; Inomata N; Uemura H; Kohashi S; Nagao K; Harada Y; Miki M; Juri N; Irie Y; Kanzawa M; Itoh T; Inoue J; Imai T; Fukumoto T; Kodama Y
    J Gastroenterol; 2023 Oct; 58(10):1055-1067. PubMed ID: 37477731
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Role of Immune Microenvironment in pancreatic Ductal Adenocarcinoma: Could It Be Considered a Predictor of Prognosis?
    De Simoni O; Dal Santo L; Scarpa M; Munari G; Spolverato YC; Scapinello A; Lonardi S; Soldà C; Bergamo F; Fantin A; Bardini R; Pilati P; Fassan M; Gruppo M
    Curr Oncol; 2023 Jun; 30(6):5515-5528. PubMed ID: 37366900
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. MHC class I loss is associated with biliary/progenitor cell features and "cold" tumor-immune microenvironment in hepatocellular carcinoma.
    Shigematsu Y; Amori G; Tanaka K; Kitahama K; Kanda H; Takahashi Y; Takazawa Y; Takeuchi K; Inamura K
    Virchows Arch; 2023 Aug; 483(2):177-186. PubMed ID: 37306724
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Association of Sarcopenia with a Poor Prognosis and Decreased Tumor-Infiltrating CD8-Positive T Cells in pancreatic Ductal Adenocarcinoma: A Retrospective Analysis.
    Masuda S; Yamakawa K; Masuda A; Toyama H; Sofue K; Nanno Y; Komatsu S; Omiya S; Sakai A; Kobayashi T; Tanaka T; Tsujimae M; Ashina S; Gonda M; Abe S; Uemura H; Kohashi S; Inomata N; Nagao K; Harada Y; Miki M; Irie Y; Juri N; Kanzawa M; Itoh T; Fukumoto T; Kodama Y
    Ann Surg Oncol; 2023 Sep; 30(9):5776-5787. PubMed ID: 37191859
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and foxp3+ cancer Cells in Locally Advanced pancreatic cancer.
    Boucher Y; Posada JM; Subudhi S; Kumar AS; Rosario SR; Gu L; Kumra H; Mino-Kenudson M; Talele NP; Duda DG; Fukumura D; Wo JY; Clark JW; Ryan DP; Fernandez-Del Castillo C; Hong TS; Pittet MJ; Jain RK
    Clin Cancer Res; 2023 Apr; 29(8):1605-1619. PubMed ID: 36749873
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Integrated analysis of tertiary lymphoid structures in relation to tumor-infiltrating lymphocytes and patient survival in pancreatic ductal adenocarcinoma.
    Tanaka T; Masuda A; Inoue J; Hamada T; Ikegawa T; Toyama H; Sofue K; Shiomi H; Sakai A; Kobayashi T; Tanaka S; Nakano R; Yamada Y; Ashina S; Tsujimae M; Yamakawa K; Abe S; Gonda M; Masuda S; Inomata N; Uemura H; Kohashi S; Nagao K; Kanzawa M; Itoh T; Ueda Y; Fukumoto T; Kodama Y
    J Gastroenterol; 2023 Mar; 58(3):277-291. PubMed ID: 36705749
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Tumor-infiltrating lymphocytes and macrophages as a significant prognostic factor in biliary tract cancer.
    Tanaka R; Eguchi S; Kimura K; Ohira G; Tanaka S; Amano R; Tanaka H; Yashiro M; Ohira M; Kubo S
    PLoS One; 2023; 18(1):e0280348. PubMed ID: 36693070
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 9.